RxSight Issues Lower 2026 Revenue & Margin Guidance Following Mixed 2025 Results
RXST sits 39% above its 52-week low of $6.32.
Summary
RxSight reported a 4% revenue decrease and widened net loss for full-year 2025, while providing 2026 guidance that projects lower revenue and gross margins, signaling a challenging outlook.
Key Events · Earnings and Guidance · RXST
-
Issues Lower 2026 Financial Guidance
The company projects full-year 2026 revenue between $120.0 million and $135.0 million, a potential decrease from 2025's $134.5 million. Gross margin is guided to be 70% to 72%, down from 76.6% in 2025, primarily due to lower Light Delivery Device (LDD) production volumes.
-
Reports Mixed Full-Year 2025 Results
Global sales for 2025 decreased 4% year-over-year to $134.5 million, with a 12% increase in Light Adjustable Lens (LAL) unit sales offset by a 48% decrease in LDD system sales. Net loss widened significantly to $(38.9) million, or $(0.95) per share, compared to $(27.5) million in 2024.
-
Q4 2025 Revenue Declined
Total revenue for the fourth quarter of 2025 was $32.6 million, a 19% decrease compared to $40.2 million in Q4 2024, largely reflecting a 72% decline in LDD revenue. Net loss for the quarter was $(9.2) million, or $(0.22) per share.
Analysis · RXST · Industrial Applications And Services
RxSight, Inc. reported a mixed financial performance for full-year 2025, with overall revenue decreasing by 4% year-over-year to $134.5 million, despite a 12% growth in Light Adjustable Lens (LAL) unit sales. However, the company's net loss significantly widened to $(38.9) million from $(27.5) million in 2024. The most impactful aspect of this filing is the company's 2026 financial guidance, which projects revenue of $120.0 to $135.0 million, representing a potential decrease from 2025's actuals, and a lower gross margin of 70% to 72% compared to 76.6% in 2025. This downward revision in future outlook for both top-line growth and profitability signals a challenging period ahead. This guidance follows closely after the company filed a post-effective amendment to its S-3 registration statement on February 13, 2026, for a potential $200 million offering, indicating a need for capital that is now underscored by a weaker financial outlook.
At the time of this filing, RXST was trading at $8.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $362.2M. The 52-week trading range was $6.32 to $29.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.